Merck, Serum Institute Face-off Looms With HPV Vaccination Support In India’s Interim Budget
Serum To Hike Capacity, Will Merck Drop Prices?
A mention in India’s interim budget of support for HPV vaccination is heartening for Serum Institute and Merck as it is seen as a precursor to the vaccine’s inclusion in the country’s Universal Immunization Program, one of the largest public health programs globally. As Serum plans to expand capacity, will Merck drop Gardasil prices for a piece of the UIP pie?
You may also be interested in...
FDA’s observations at Aurobindo subsidiary Eugia's plant in India and a new one in New Jersey could lead to more drug shortages in the US, particularly injectables, though the company aims to streamline production by end-March. Meanwhile, it will capitalize on the “sizable opportunity” from the EU's list of critical medicines while launching a Herceptin biosimilar in India
The company expects new products like the pneumococcal vaccine V116, the PAH treatment sotatercept and the ADC patritumab deruxtecan will begin contributing to revenue growth in the near term.
GSK’s RSV vaccine Arexvy is a clear early winner against Pfizer’s rival, prompting analysts to finally turn optimistic about the company’s long-term prospects.